Quibim

Quibim envisions a future where medical imaging transcends traditional diagnostics to become a cornerstone of precision medicine, unlocking the full potential of imaging data to drastically improve patient outcomes worldwide.

By harnessing the power of artificial intelligence and advanced imaging biomarkers, we create intelligent solutions that transform complex MRI, CT, and PET scan data into actionable clinical insights. Our regulatory-cleared platforms enable healthcare and life sciences pioneers to advance diagnosis, accelerate drug development, and personalize treatment strategies like never before.

At Quibim, we are committed to redefining healthcare through innovation and data-driven technology, building a future where imaging is seamlessly integrated into clinical workflows to empower clinicians and improve lives on a global scale.

We'll be honest — when we first heard about Quibim, we weren't expecting much. Another AI medical imaging company? How groundbreaking could it really be? But after digging into what this Spanish biotech is actually doing, we're genuinely impressed.

Founded by two imaging experts who spent years identifying gaps in clinical radiology, Quibim isn't just throwing AI at medical scans and hoping for the best. They're systematically turning MRI, CT, and PET imaging data into precise, actionable predictions that actually matter for patient outcomes.

What Makes Them Different

Here's where Quibim gets interesting: they're not just building diagnostic tools. Their Precision Platform extracts what they call "imaging biomarkers" — basically, hidden patterns in medical scans that can predict how patients will respond to treatments or whether diseases will progress.

We've seen plenty of AI companies claim they can "revolutionize healthcare," but Quibim's got the regulatory clearances to back it up. CE marks, FDA 510(k) approvals, and partnerships with over 70 hospitals worldwide tell a story of actual clinical adoption, not just demo videos.

The Numbers That Caught Our Attention

Sometimes growth metrics can be misleading, but Quibim's trajectory is hard to ignore. They went from research project to commercial operations in 2020, then saw 5x revenue growth in 2022 alone. That's the kind of scaling that happens when you're solving real problems.

Even more telling? They've built a repository of over 10 million de-identified imaging data points and are working across 11 clinical trials. That's not hype — that's infrastructure.

Who Should Care

If you're in biopharma and struggling with clinical trial recruitment or drug response prediction, Quibim's platform could be a game-changer. Their partnerships with heavy hitters like Merck Serono and Novartis suggest the pharma world is taking notice.

For hospitals, their organ-specific tools (QP-Prostate, QP-Brain, QP-Liver) promise to reduce diagnostic errors and cut down on unnecessary re-examinations. The NHS is already rolling out their prostate cancer detection tool across seven hospitals, which feels like a pretty solid endorsement.

Bottom line: Quibim feels like one of those rare companies that's found the sweet spot between cutting-edge AI and practical clinical utility. We'll be watching their next moves closely.